E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce Fourth Quarter and Year Ended December 31, 2022 Financial Results on Wednesday, March 8
01 mars 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial...
Featured Image for SportGait
SPORTGAIT'S BKG (trademarked) PATENTED GAIT TECHNOLOGY PREDICTIVE CAPABILITIES VETTED AND PUBLISHED
23 févr. 2023 13h16 HE | SportGait (sportgait.com)
WILMINGTON, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- SportGait, the brain wellness and medical technology company, proudly announced today the publication of an article in the Journal of Concussion...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa
21 févr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
16 févr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Completes Sale of New Jersey Tax Benefits
15 févr. 2023 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Reverse Stock Split
14 févr. 2023 10h30 HE | electroCore, Inc.
ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update
17 janv. 2023 08h00 HE | electroCore, Inc.
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022Revenue growth of approximately 57% over full-year 2021Launched two new...
New Logo July 12, 2022.png
Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
12 janv. 2023 08h30 HE | Odyssey Health, Inc
Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™
20 déc. 2022 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called...
New Logo July 12, 2022.png
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
19 déc. 2022 08h30 HE | Odyssey Health, Inc
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today...